Abstract of a meta-analysis--from PubMed, January 28, 2016:
JAMA. 2016 Jan 26;315(4):409-10. doi: 10.1001/jama.2015.18984.
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis
Tramacere I1, Del Giovane C2, Filippini G3.
Author information
1Neuroepidemiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
2Italian Cochrane Centre, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy.
3Scientific Direction, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
CLINICAL QUESTION:
What immunotherapies for multiple sclerosis are associated with the greatest benefit and highest risk of discontinuation due to adverse events in patients with relapsing-remitting multiple sclerosis?
BOTTOM LINE:
Alemtuzumab, natalizumab, and fingolimod were associated with the greatest benefit with regard to relapse prevention. Their association with prevention of disability worsening was unclear. Fingolimod was associated with a high risk of treatment discontinuation due to adverse events.
Comment on
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. [Cochrane Database Syst Rev. 2015]